Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 105

1.

Guillain-Barré and Miller Fisher syndromes in patients with anti-hepatitis E virus antibody: a hospital-based survey in Japan.

Fukae J, Tsugawa J, Ouma S, Umezu T, Kusunoki S, Tsuboi Y.

Neurol Sci. 2016 Nov;37(11):1849-1851.

PMID:
27389141
2.

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib.

Ohyashiki K, Umezu T, Katagiri S, Kobayashi C, Azuma K, Tauchi T, Okabe S, Fukuoka Y, Ohyashiki JH.

Int J Mol Sci. 2016 Apr 15;17(4):570. doi: 10.3390/ijms17040570.

3.

Exosomes promote bone marrow angiogenesis in hematologic neoplasia: the role of hypoxia.

Ohyashiki JH, Umezu T, Ohyashiki K.

Curr Opin Hematol. 2016 May;23(3):268-73. doi: 10.1097/MOH.0000000000000235. Review.

PMID:
26866730
4.

[Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib].

Katagiri S, Tauchi T, Umezu T, Saito Y, Suguro T, Asano M, Yoshizawa S, Kitahara T, Akahane D, Tanaka Y, Fujimoto H, Okabe S, Gotoh M, Ito Y, Ohyashiki JH, Ohyashiki K.

Rinsho Ketsueki. 2015 Feb;56(2):216-9. doi: 10.11406/rinketsu.56.216. Japanese.

PMID:
25765803
5.

Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.

Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki JH.

Blood. 2014 Dec 11;124(25):3748-57. doi: 10.1182/blood-2014-05-576116.

6.

Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?

Kajiyama H, Mizuno M, Shibata K, Umezu T, Suzuki S, Yamamoto E, Mitsui H, Sekiya R, Niimi K, Kawai M, Nagasaka T, Kikkawa F.

Eur J Obstet Gynecol Reprod Biol. 2014 Oct;181:305-10. doi: 10.1016/j.ejogrb.2014.07.046.

PMID:
25203309
7.

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely.

Ohyashiki JH, Ohtsuki K, Mizoguchi I, Yoshimoto T, Katagiri S, Umezu T, Ohyashiki K.

Drug Des Devel Ther. 2014 Aug 25;8:1151-9. doi: 10.2147/DDDT.S66812.

8.

Different behavioral effect dose-response profiles in mice exposed to two-carbon chlorinated hydrocarbons: influence of structural and physical properties.

Umezu T, Shibata Y.

Toxicol Appl Pharmacol. 2014 Sep 1;279(2):103-12. doi: 10.1016/j.taap.2014.05.012.

PMID:
24910396
9.

Opioid needs of terminally ill patients with gynecologic malignancies.

Utsumi F, Kajiyama H, Sakata J, Higashi M, Niimi K, Sekiya R, Mitsui H, Suzuki S, Umezu T, Mizuno M, Yamamoto E, Shibata K, Kikkawa F.

Int J Clin Oncol. 2015 Apr;20(2):405-10. doi: 10.1007/s10147-014-0708-0.

PMID:
24906849
10.

Possible association between stem-like hallmark and radioresistance in human cervical carcinoma cells.

Kumazawa S, Kajiyama H, Umezu T, Mizuno M, Suzuki S, Yamamoto E, Mitsui H, Sekiya R, Shibata K, Kikkawa F.

J Obstet Gynaecol Res. 2014 May;40(5):1389-98. doi: 10.1111/jog.12357.

PMID:
24750491
11.

Constitutive activation of the ATM/BRCA1 pathway prevents DNA damage-induced apoptosis in 5-azacytidine-resistant cell lines.

Imanishi S, Umezu T, Ohtsuki K, Kobayashi C, Ohyashiki K, Ohyashiki JH.

Biochem Pharmacol. 2014 Jun 1;89(3):361-9. doi: 10.1016/j.bcp.2014.03.008.

PMID:
24680865
12.

Is there any association between where patients spend the end of life and survival after anticancer treatment for gynecologic malignancy?

Kajiyama H, Utsumi F, Higashi M, Sakata J, Sekiya R, Mizuno M, Umezu T, Suzuki S, Yamamoto E, Mitsui H, Niimi K, Shibata K, Kikkawa F.

J Palliat Med. 2014 Mar;17(3):325-30. doi: 10.1089/jpm.2013.0366.

PMID:
24617316
13.

Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology.

Kajiyama H, Shibata K, Mizuno M, Umezu T, Suzuki S, Sekiya R, Niimi K, Mitsui H, Yamamoto E, Kawai M, Nagasaka T, Kikkawa F.

J Gynecol Oncol. 2014 Jan;25(1):43-50. doi: 10.3802/jgo.2014.25.1.43.

14.

A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age.

Kajiyama H, Mizuno M, Shibata K, Umezu T, Suzuki S, Yamamoto E, Mitsui H, Sekiya R, Niimi K, Kawai M, Nagasaka T, Kikkawa F.

Int J Clin Oncol. 2014 Oct;19(5):921-7. doi: 10.1007/s10147-013-0645-3.

PMID:
24306200
15.

Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells.

Tadokoro H, Umezu T, Ohyashiki K, Hirano T, Ohyashiki JH.

J Biol Chem. 2013 Nov 29;288(48):34343-51. doi: 10.1074/jbc.M113.480822.

16.

A patient who experienced thyroid storm complicated by rhabdomyolysis, deep vein thrombosis, and a silent pulmonary embolism: a case report.

Umezu T, Ashitani K, Toda T, Yanagawa T.

BMC Res Notes. 2013 May 20;6:198. doi: 10.1186/1756-0500-6-198.

17.

Structure of perosamine-containing polysaccharide, a component of the sheath of Thiothrix fructosivorans.

Kondo K, Umezu T, Shimura S, Narizuka R, Koizumi J, Mashima T, Katahira M, Takeda M.

Int J Biol Macromol. 2013 Aug;59:59-66. doi: 10.1016/j.ijbiomac.2013.04.013.

PMID:
23587998
18.

The expression and characterization of endoglin in uterine leiomyosarcoma.

Mitsui H, Shibata K, Mano Y, Suzuki S, Umezu T, Mizuno M, Yamamoto E, Kajiyama H, Kotani T, Senga T, Kikkawa F.

Clin Exp Metastasis. 2013 Aug;30(6):731-40. doi: 10.1007/s10585-013-9574-9.

PMID:
23397382
19.

Clinical relevance of plasma miR-106b levels in patients with chronic obstructive pulmonary disease.

Soeda S, Ohyashiki JH, Ohtsuki K, Umezu T, Setoguchi Y, Ohyashiki K.

Int J Mol Med. 2013 Mar;31(3):533-9. doi: 10.3892/ijmm.2013.1251.

PMID:
23338559
20.

Contrast-enhanced ultrasonography using Sonazoid(®) is useful for diagnosis of malignant ovarian tumors: comparison with Doppler ultrasound.

Kumazawa S, Umezu T, Kanayama Y, Kamiyama N, Suzuki S, Mizuno M, Kajiyama H, Shibata K, Kikkawa F.

J Med Ultrason (2001). 2013 Jan;40(1):81-4. doi: 10.1007/s10396-012-0380-9.

PMID:
27276932
Items per page

Supplemental Content

Support Center